| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
103,650,000 |
| Market
Cap: |
1.54(B) |
| Last
Volume: |
772,336 |
Avg
Vol: |
1,689,102 |
| 52
Week Range: |
$11.5 - $17.51 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drugs - Generic |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 604 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Catalyst Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing medicines for patients living with rare diseases. Co.'s primary product, Firdapse®, is used for the treatment of adult patients (ages 17 and above) with Lambert-Eaton, Myasthenic Syndrome, a rare autoimmune neuromuscular disorder characterized by muscle weakness of the limbs. Co. has developed its vigabatrin (CPP-109) as a generic version of Sabril®. Co. has an agreement with Endo International plc's subsidiary, Endo Ventures Limited, for the development and commercialization of generic Sabril® tablets through Endo's U.S. Generic Pharmaceuticals segment, Par Pharmaceutical.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
50,000 |
304,000 |
330,151 |
4,223,516 |
| Total Sell Value |
$803,000 |
$4,338,050 |
$4,684,028 |
$62,649,148 |
| Total People Sold |
2 |
6 |
7 |
12 |
| Total Sell Transactions |
2 |
8 |
9 |
53 |
| End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Del Carmen Jeffrey |
Chief Commercial Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,666 |
10,666 |
|
- |
|
| Grande Alicia |
VP, Treasurer and CFO |
• – – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,718) |
50,557 |
|
- |
|
| Grande Alicia |
VP, Treasurer and CFO |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,166 |
53,275 |
|
- |
|
| Ingenito Gary |
Chief Medical Officer |
• – – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,435) |
38,367 |
|
- |
|
| Ingenito Gary |
Chief Medical Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
40,802 |
|
- |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,353) |
138,076 |
|
- |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,666 |
140,429 |
|
- |
|
| Daly Richard J |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
98,000 |
|
- |
|
| Sundaram Preethi |
Chief Strategy Officer |
• – – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(6,024) |
10,642 |
|
- |
|
| Sundaram Preethi |
Chief Strategy Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
16,666 |
16,666 |
|
- |
|
| Miller Steve |
Chief Operating Officer |
• – – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,666 |
587,457 |
|
- |
|
| Denkhaus Donald A |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
333,000 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
154,887 |
|
- |
|
| Harper Molly |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
4,000 |
|
- |
|
| Mcenany Patrick J |
President and CEO |
• • – |
2023-02-15 |
4 |
D |
$0.00 |
$0 |
D/D |
(14,204) |
3,945,436 |
|
- |
|
| Mcenany Patrick J |
President and CEO |
• • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
58,333 |
3,959,640 |
|
- |
|
| O'keeffe Charles B |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
620,391 |
|
- |
|
| Tierney David S |
Director |
– • – |
2023-02-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,000 |
313,541 |
|
- |
|
| O'keeffe Charles B |
Director |
– • – |
2023-01-24 |
4 |
OE |
$0.79 |
$39,500 |
D/D |
50,000 |
616,391 |
|
- |
|
| Denkhaus Donald A |
Director |
– • – |
2023-01-24 |
4 |
OE |
$0.79 |
$39,500 |
D/D |
50,000 |
329,000 |
|
- |
|
| Mcenany Patrick J |
President and CEO |
• • – |
2022-12-29 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
3,901,307 |
|
- |
|
| Mcenany Patrick J |
President and CEO |
• • – |
2022-12-28 |
4 |
GD |
$0.00 |
$0 |
D/D |
10,000 |
3,911,307 |
|
- |
|
| Elsbernd Brian |
Chief Compliance/Legal Officer |
• – – |
2022-12-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,667 |
130,763 |
|
- |
|
| Miller Steve |
Chief Operating Officer |
• – – |
2022-12-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
20,000 |
573,791 |
|
- |
|
| Coelho Philip H |
Director |
– • – |
2022-12-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,334 |
150,887 |
|
- |
|
312 Records found
|
|
Page 4 of 13 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.21 (1.43%) 
